Ocular Hypertension - Pipeline Review, H1 2018

  • ID: 4473086
  • Report
  • 124 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • NicOx SA
  • Ocular Therapeutix Inc
  • Sylentis SAU
  • MORE
Ocular Hypertension - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2018, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 11, 14, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • NicOx SA
  • Ocular Therapeutix Inc
  • Sylentis SAU
  • MORE
Introduction

Report Coverage

Ocular Hypertension - Overview

Ocular Hypertension - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ocular Hypertension - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ocular Hypertension - Companies Involved in Therapeutics Development

Aerie Pharmaceuticals Inc

Aerpio Therapeutics Inc

Allergan Plc

Can-Fite BioPharma Ltd

D. Western Therapeutics Institute Inc

F. Hoffmann-La Roche Ltd

Ironwood Pharmaceuticals Inc

Laboratoires Thea SA

Laboratorios Sophia SA de CV

Lee's Pharmaceutical Holdings Ltd

Neurim Pharmaceuticals Ltd

NicOx SA

Novartis AG

Ocular Therapeutix Inc

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Shire Plc

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

Taejoon Pharm Co Ltd

Ocular Hypertension - Drug Profiles

(bimatoprost + timolol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + netarsudil mesylate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + timolol maleate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKB-9778 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bamosiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimatoprost ocular insert - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimatoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimonidine tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-1129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IWP-953 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levobetaxolol hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGV-354 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-1653 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-470 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-667 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netarsudil mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omidenepag isopropyl - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRO-067 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRO-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7945 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5093151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sepetaprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-639 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SJP-0125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SJP-0135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

timolol maleate CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TJO-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost XR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ocular Hypertension - Dormant Projects

Ocular Hypertension - Discontinued Products

Ocular Hypertension - Product Development Milestones

Featured News & Press Releases

Dec 18, 2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Nov 27, 2017: Santen Files for Manufacturing and Marketing Approval of Glaucoma and Ocular Hypertension Drug Candidate DE-117 (JAN: Omidenepag Isopropyl)

Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan

Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02%

Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02%

Sep 06, 2017: Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer

Jul 19, 2017: Aerie Pharmaceuticals Reports Positive Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results

May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02%

May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2

May 02, 2017: Ocular Therapeutix to Present Data on OTX-TP (travoprost insert) at the Association for Research in Vision and Ophthalmology Annual Meeting

Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%

Mar 15, 2017: D. Western Therapeutics Institute Announces Completion of Phase I Clinical Study with WP-1

Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2

Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Ocular Hypertension, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H1 2018

Ocular Hypertension - Pipeline by Aerpio Therapeutics Inc, H1 2018

Ocular Hypertension - Pipeline by Allergan Plc, H1 2018

Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd, H1 2018

Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H1 2018

Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018

Ocular Hypertension - Pipeline by Laboratoires Thea SA, H1 2018

Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, H1 2018

Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018

Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2018

Ocular Hypertension - Pipeline by NicOx SA, H1 2018

Ocular Hypertension - Pipeline by Novartis AG, H1 2018

Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, H1 2018

Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, H1 2018

Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, H1 2018

Ocular Hypertension - Pipeline by Shire Plc, H1 2018

Ocular Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Ocular Hypertension - Pipeline by Sylentis SAU, H1 2018

Ocular Hypertension - Pipeline by Taejoon Pharm Co Ltd, H1 2018

Ocular Hypertension - Dormant Projects, H1 2018

Ocular Hypertension - Dormant Projects, H1 2018 (Contd..1), H1 2018

Ocular Hypertension - Discontinued Products, H1 2018

Ocular Hypertension - Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures:

Number of Products under Development for Ocular Hypertension, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aerie Pharmaceuticals Inc
  • Aerpio Therapeutics Inc
  • Allergan Plc
  • Can-Fite BioPharma Ltd
  • D. Western Therapeutics Institute Inc
  • F. Hoffmann-La Roche Ltd
  • Ironwood Pharmaceuticals Inc
  • Laboratoires Thea SA
  • Laboratorios Sophia SA de CV
  • Lee's Pharmaceutical Holdings Ltd
  • Neurim Pharmaceuticals Ltd
  • NicOx SA
  • Novartis AG
  • Ocular Therapeutix Inc
  • Santen Pharmaceutical Co Ltd
  • Senju Pharmaceutical Co Ltd
  • Shire Plc
  • Sun Pharma Advanced Research Company Ltd
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll